Supplementary material

	Excluded symptoms					
Creation in the model						
	lump on the lower extremity					
	pustule in the armpit					
	indurated skin of the armpit					
	indurated skin of the groin					
	scarring in the groin					
	scarring in the armpit					
	pruritic armpit					
	erythema of the armpit					
	proctitis on examination					
	recurrent candidiasis in females					
	recurrent candidiasis in males					
	ear abscess					
	penile discharge foreskin					
	hyphema					
	raised bumps on the glans penis					
	raised bumps on the penis shaft					
	spot on the glans penis					
	spot on the penis shaft					
Deletion from the model						
	recurrent candidiasis					
	severe acute respiratory syndrome associated coronavirus					
Modification in associated terms						
	alopecia					
	thinning hair					
	spot on the penis					

Table 1. Excluded symptoms from the analysis

Table 2. Relative difference (log2 fold change values) in the proportions of Ada users' reported symptoms with statistically significant differences between the Baseline and COVID-19 Measures periods in Germany

ICD-10 groups & symptoms	Baseline (%)	Measures (%)	log2 fold change	<i>P</i> value ^a
Cognition, perception, emotional state,				
and behaviour				
diminished sense of taste ^b	.10	.48	2.26	<.001
hyposmia ^b	.05	.24	2.20	<.001
bad taste in mouth	.27	.41	.62	.002
depressed mood ^b	2.71	2.02	42	<.001
loss of motivation	.94	.59	67	<.001
inability to manage constant stress and demands at work ^b	.43	.21	-1.07	<.001
impaired concentration ^b	1.24	.91	46	<.001
dizziness	8.53	7.75	14	<.001
memory difficulty ^b	.57	.39	56	<.001
teeth grinding	.09	.04	-1.26	.033
aggressive behavior	.36	.25	51	.046
Nervous system				
excessive daytime sleepiness ^b	2.74	1.9	53	<.001
General symptoms and signs				
lowered temperature of the foot ^b	.34	.55	.71	<.001
body temperature decreased	.06	.14	1.12	.005
malaise ^b	2.53	1.25	-1.02	<.001
fatigue ^b	9.24	7.35	33	<.001
chills ^b	3.88	2.78	48	<.001
fever	6.32	4.95	35	<.001
headache	19.90	17.90	16	<.001
reduced performance	1.96	1.51	37	<.001
abulia	.66	.45	56	<.001
tenderness head	1.24	.97	36	.001
hyperhidrosis generalized	1.98	1.70	23	.015
Musculoskeletal system				
mark from bug bite	.04	.17	2.12	<.001
myalgia ^b	4.11	2.52	71	<.001
muscle cramps in the lower extremity	.38	.26	57	.014
feeling of heavy limbs	.11	.05	-1.10	.029
feeling of unstable knee	.08	.04	-1.25	.047
Digestive system and abdomen				
odynophagia ^b	3.99	2.33	77	<.001
vomiting ^b	2.62	1.83	51	<.001
nausea ^b	10.90	10.00	13	<.001
diarrhea ^b	5.90	5.37	14	.007

Speech and voice				- ·
hoarseness ^b	.77	.36	-1.10	<.001
odynophonia ^b	.37	.24	64	.004
aphonia ^b	.06	.02	-1.64	.047
Eye and adnexa				
otalgia ^b	2.93	1.93	61	<.001
inability to clear the ear with changing				
barometric pressure ^b	.52	.31	77	<.001
aural fullness ^b	.85	.60	51	<.001
post orbital pain	1.92	1.59	27	.003
hearing deficit	.47	.34	49	.017
ocular discharge	.15	.08	87	.046
Circulatory and respiratory systems			,	
dyspnea ^b	3.67	5.38	.55	<.001
sneezing	.69	1.31	.93	<.001
chest pain ^b	7.11	8.34	.23	<.001
tragal tenderness	.05	.19	1.84	<.001
throat tightness	1.11	1.47	.40	<.001
sternal pain	.18	.28	.69	.009
dry throat	.59	.77	.39	.011
throat clearing ^b	.16	.26	.71	.011
nasal discharge ^b	7.20	4.75	60	<.001
sore throat ^b	8.44	6.14	46	<.001
cough ^b	12.90	10.20	34	<.001
sinus pain ^b	.71	.43	73	<.001
nasal congestion ^b	3.32	2.71	29	<.001
recurrent respiratory tract infections	.64	.39	73	<.001
Skin and subcutaneous tissue				
pruritic eyes ^b	.38	.81	1.10	<.001
dry skin of the hands ^b	.20	.46	1.21	<.001
skin rash of the hand	.27	.52	.97	<.001
skin rash of the upper extremity	.27	.46	.76	<.001
spot on the upper extremity ^b	.15	.30	.98	<.001
pruritic nasal cavity ^b	.16	.30	.94	<.001
pruritic hand	.13	.23	.90	.001
scaling skin of the intertriginous areas	.01	.05	2.51	.003
indurated skin of the foot	.00	.04	3.27	.011
skin rash of the antecubital fossa	.02	.07	1.61	.011
spot on the hand	.05	.11	1.11	.023
pruritic penis	.16	.08	92	.021
Genitourinary system				
breast tenderness	1.13	1.48	.39	<.001
pustule on the male genital	.07	.03	-1.40	.048

^a Pearson chi-square test for differences between Baseline and Measures. *P* values were adjusted for multiple testing using the false discovery rate method. ^b symptoms were also found to be significantly different between the Baseline and the Measures period in the United Kingdom

ICD-10 groups & symptoms	Baseline (%)	Measures (%)	log2 fold change	<i>P</i> value ^a
Cognition, perception, emotional state,	(/*)	(/)	······································	,
and behaviour				
hyposmia ^b	.07	.96	3.74	<.001
diminished sense of taste ^b	.09	.98	3.38	<.001
olfactory hallucination	.04	.11	1.49	.023
depressed mood ^b	4.11	2.49	72	<.001
anxiety	2.72	1.71	67	<.001
social phobia	.66	.31	-1.08	<.001
inability to manage constant stress and	.35	.13	-1.43	<.001
demands at work ^b				
impaired concentration ^b	1.71	1.18	53	<.001
memory difficulty ^b	.72	.43	73	<.001
previous depressive episode	.40	.21	94	<.001
suicidal tendencies	.79	.52	61	<.001
crying	.77	.52	57	.001
mood lability	1.39	1.08	35	.009
excessive worry	.51	.33	61	.010
extreme fear of situations with difficulty to	.16	.07	-1.26	.010
escape or to get help				
Nervous system				
excessive daytime sleepiness ^b	2.10	1.57	43	<.001
poorly restorative sleep	.62	.43	53	.015
General symptoms and signs				
lowered temperature of the foot ^b	.37	.56	.60	.006
fatigue ^b	12.70	10.10	33	<.001
malaise ^b	3.54	2.31	61	<.001
chills ^b	4.21	3.36	33	<.001
binge eating	.46	.24	91	<.001
cervical lymphadenopathy	1.25	.92	44	.001
weight gain	.66	.43	61	.002
irritability pediatric patient	.17	.07	-1.26	.007
weight loss	.59	.42	51	.025
Musculoskeletal system				
generalized arthralgia	1.04	.75	48	.001
hip pain	1.18	.93	34	.027
imbalance	.32	.20	69	.037
myalgia ^b	3.86	3.42	17	.037
Digestive system and abdomen				

Table 3. Relative difference (log2 fold change values) in the proportions of Ada users' reported symptoms with statistically significant differences between the Baseline and COVID-19 Measures periods in the United Kingdom

gingival swelling	.09	.18	.95	.049		
vomiting ^b	3.11	2.15	53	<.001		
odynophagia ^b	1.29	.75	78	<.001		
nausea ^b	12.50	11.40	14	<.001		
diarrhea ^b	5.81	5.10	19	.001		
abdominal pain	18.10	17.00	09	.001		
flatulence	1.69	1.38	30	.018		
change in stool color	.64	0.47	45	.046		
Speech and voice	101	0.17	110	1010		
aphonia ^b	.26	.07	-1.87	<.001		
odynophonia ^b	.47	.21	-1.17	<.001		
hoarseness ^b	.37	.23	68	.020		
Eye and adnexa	,	.23	.00	.020		
inability to clear the ear with changing						
barometric pressure ^b	.37	.21	85	.002		
aural fullness ^b	1.03	.77	42	.008		
otalgia ^b	3.00	2.62	20	.040		
Circulatory and respiratory systems						
chest pain ^b	7.85	9.59	.29	<.001		
pruritic throat	.49	.74	.59	.001		
dyspnea ^b	5.71	6.45	.18	.001		
throat clearing ^b	.15	.28	.90	.006		
nasal pain	.41	.58	.49	.036		
muscular tenseness of the chest muscles	.17	.28	.72	.047		
sore throat ^b	10.50	7.20	55	<.001		
nasal discharge ^b	5.63	3.31	77	<.001		
nasal congestion ^b	5.16	3.61	51	<.001		
sinus pain ^b	2.66	2.14	31	<.001		
cough ^b	13.60	12.60	11	.005		
tonsillopharyngeal exudate	.46	.31	59	.023		
tonsillar enlargement	.43	.28	61	.026		
Skin and subcutaneous tissue						
pruritic eyes ^b	.44	.89	1.02	<.001		
pruritic nasal cavity ^b	.10	.28	1.52	<.001		
urticaria	.18	.33	.86	.004		
<i>dry skin of the hands</i> ^b	.14	.28	.96	.004		
scaling skin of the face	.05	.13	1.38	.015		
spot on the upper extremity ^b	.18	.30	.72	.037		
scrotal pruritus	.16	.06	-1.27	.011		
Genitourinary system						
vaginal pain	.62	.44	51	.019		
Pearson chi-square test for differences between Baseline and Measures <i>P</i> values were						

^a Pearson chi-square test for differences between Baseline and Measures. *P* values were adjusted for multiple testing using the false discovery rate method.

^b symptoms were also found to be significantly different between the Baseline and the Measures period in Germany

ICD-10 groups & symptoms	Baseline (%)	Measures (%)	log2 fold change	<i>P</i> value ^a
General symptoms and signs				
malaise	2.57	1.82	50	<.001
fatigue	8.97	7.98	17	.014
chills	4.01	2.61	62	<.001
fever	5.67	3.65	64	<.001
headache	21.1	17.6	26	<.001
Musculoskeletal system				
myalgia	4.03	2.76	55	<.001
Circulatory and respiratory systems				
nasal discharge	8.15	6.24	39	<.001
sore throat	8.53	7.12	26	<.001
cough	11.3	8.8	37	<.001
sinus pain	.84	.56	59	.029

Table 4. Relative difference (log2 fold change values) in the proportions of Ada users' reported symptoms with statistically significant differences between the same period as the Baseline and COVID-19 Measures periods in 2019 in Germany

^a Pearson chi-square test for differences between Baseline and Measures. *P* values were adjusted for multiple testing using the false discovery rate method.

Table 5. Relative difference (log2 fold change values) in the proportions of Ada users' reported symptoms with statistically significant differences between the same period as the Baseline and COVID-19 Measures periods in 2019 in the United Kingdom

ICD-10 groups & symptoms	Baseline (%)	Measures (%)	log2 fold change	P value ^a
Genitourinary system				
breast tenderness	2.59	1.85	49	<.001

^a Pearson chi-square test for differences between Baseline and Measures. *P* values were adjusted for multiple testing using the false discovery rate method.

	Tempe	erature	Precip	Precipitation		shine
C (•	Р		Р		Р
Symptoms	ρ	value ^a	ρ	value ^a	ρ	value ^a
dyspnea	.08	.825	.02	.964	.25	.458
diminished sense of taste	46	.145	.05	.964	25	.458
pruritic eyes	.50	.116	37	.964	.76	.023
hyposmia	34	.301	04	.964	14	.700
chest pain	80	.007	.09	.964	67	.061
dry skin of the hands	51	.104	37	.964	09	.773
lowered temperature of the foot	86	.003	.09	.964	79	.023
spot on the upper extremity	.80	.007	09	.964	.75	.023
pruritic nasal cavity	.49	.116	49	.917	.77	.023
throat clearing	.03	.917	06	.964	.26	.458
nasal discharge	60	.052	02	.964	41	.243
odynophagia	68	.027	04	.964	60	.070
malaise	64	.040	.17	.964	59	.070
myalgia	74	.012	.05	.964	62	.070
sore throat	53	.104	.02	.964	33	.349
cough	75	.011	.06	.964	60	.070
fatigue	41	.196	.05	.964	28	.456
otalgia	73	.014	.08	.964	58	.071
chills	77	.010	.03	.964	64	.070
excessive daytime sleepiness	.17	.638	.23	.964	.05	.856
hoarseness	61	.052	.29	.964	58	.071
vomiting	64	.040	12	.964	65	.070
depressed mood	52	.104	.32	.964	61	.070
inability to manage constant stress and demands at work	20	.572	.50	.917	55	.092
sinus pain	76	.010	.15	.964	72	.033
nasal congestion	60	.052	19	.964	34	.349
inability to clear the ear with changing barometric pressure	44	.169	.23	.964	46	.181
impaired concentration	37	.256	.18	.964	42	.240
aural fullness	52	.104	.44	.964	60	.070
nausea	.05	.890	.28	.964	17	.627
memory difficulty	15	.669	.22	.964	27	.456
odynophonia	55	.088	.03	.964	34	.349
diarrhea	.66	.035	.15	.964	.49	.147
aphonia	23	.519	49	.917	10	.773

Table 6. Correlation between the significantly different symptoms in Germany and three weather variables (temperature, precipitation, and sunshine)

^a Pearson chi-square test for differences between Baseline and Measures. *P* values were adjusted for multiple testing using the false discovery rate method.

Figure 1. Correlation between the significantly different symptoms in Germany and three weather variables (temperature, precipitation, and sunshine)

